IceCure Medical Reports Positive Results for ProSense® in Small Renal Masses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy ICCM?
Source: PRnewswire
- Clinical Trial Results: The ICESECRET trial demonstrated an impressive 89.4% recurrence-free rate for patients with tumors ≤3 cm and no prior kidney cancer at a median follow-up of four years, while the overall study population showed an 83.9% recurrence-free rate, indicating the effectiveness and durability of ProSense® in treating small renal masses.
- Patient Participation: A total of 114 patients were enrolled, with 112 evaluated at the median follow-up of four years; notably, 12 patients underwent a second cryoablation procedure at a mean of 1.73±1.2 years, showcasing the sustained efficacy and good tolerability of the treatment.
- Market Potential: With kidney cancer cases projected to exceed 80,000 new diagnoses in the U.S. alone by 2025, the findings from IceCure's study may drive broader commercial adoption of ProSense® in approved markets, addressing the urgent need for minimally invasive treatment options.
- Future Outlook: Full study results are set to be presented at the European Conference on Interventional Oncology in Basel, Switzerland, in April 2026, as IceCure aims to further solidify ProSense® as an effective treatment option for patients with small renal masses through these positive findings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.240
Low
3.00
Averages
3.00
High
3.00
Current: 0.240
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IceCure Medical Reports Q1 2026 Financial Results
- Revenue Performance: IceCure Medical reported revenue of $911,000 for Q1 2026, indicating stability and potential growth in the market despite fluctuations compared to the previous year.
- Decrease in Sales and Marketing Expenses: Sales and marketing expenses for Q1 2026 were $1,068,000, down from $1,289,000 in Q1 2025, primarily due to reduced consulting fees related to regulatory submissions, showcasing the company's efforts in cost control.
- Increase in Administrative Expenses: General and administrative expenses rose to $1,263,000 in Q1 2026 from $922,000 in Q1 2025, largely driven by increased salary expenses due to fluctuations in the exchange rate between the U.S. dollar and Israeli shekel, reflecting operational cost pressures.
- Overall Operating Expenses Rise: Total operating expenses for Q1 2026 reached $4,542,000, up from $3,875,000 in Q1 2025, primarily due to increases in research and development and administrative expenses, despite a decrease in sales and marketing costs, indicating ongoing investment in R&D to drive future growth.
See More
IceCure Medical Reports Significant Growth in Q1 Performance
- Surge in Customer Accounts: As of Q1 2026, active customer accounts using ProSense® increased by 46% compared to pre-FDA clearance, indicating strong market demand and significant future sales potential.
- Significant Revenue Growth: Revenue for Q1 2026 reached $911,000, a 26% increase from $725,000 in Q1 2025, driven primarily by increased sales in the U.S., Canada, and Mexico, reflecting successful expansion in the North American market.
- Improved Gross Margin: The gross margin increased from 30% in 2025 to 32% in Q1 2026, with gross profit rising 35% to $295,000, indicating substantial progress in cost control and sales efficiency, thereby enhancing the company's financial health.
- Increased R&D Investment: R&D expenses for Q1 2026 were $2,211,000, up from $1,664,000 in 2025, primarily for the CHOICE study, demonstrating the company's ongoing commitment to technological innovation and market expansion.
See More
IceCure Medical to Announce Q1 2026 Results and Host Conference Call
- Earnings Announcement: IceCure Medical plans to release its financial and operational results for the three months ended March 31, 2026, before the Nasdaq opens on May 12, 2026, demonstrating the company's commitment to transparency and information disclosure.
- Conference Call Details: The company will hold a conference call at 11:00 a.m. EDT on the same day to discuss the financial results and other corporate developments, which is expected to attract investor and analyst attention, thereby enhancing market confidence.
- Technological Background: IceCure focuses on developing liquid nitrogen-based cryoablation technology, providing a safe and effective treatment option for tumors, particularly in breast, kidney, bone, and lung cancers, showcasing its market potential.
- Market Outlook: With the increasing demand for minimally invasive procedures, the global sales and marketing of IceCure's ProSense® system will help the company secure a foothold in the competitive medical device market.
See More
IceCure Medical Showcases ProSense® at ASBrS Conference
- FDA-Cleared Innovation: ProSense® is the only FDA-cleared minimally invasive treatment option for low-risk breast cancer, aligning with the trend toward de-escalation in breast cancer treatment, which is expected to enhance market acceptance and drive sales growth.
- Sales Growth Expectations: The company anticipates that U.S. revenue from ProSense® systems and cryoprobes will increase by over 30% in Q1 2026 compared to the same period last year, indicating strong market demand and product recognition.
- Clinical Application Promotion: At the ASBrS 2026 Annual Meeting, IceCure's sponsored cryoablation symposium attracted breast surgeons from leading medical institutions who shared their clinical experiences with ProSense®, further promoting the adoption of this technology.
- Guideline Update: The updated ASBrS Resource Guide includes cryoablation as a recommended treatment option for low-risk early-stage breast cancer, reflecting an increase in clinical evidence and acceptance among surgeons, indicating a promising future for broader application.
See More
IceCure Medical Wins Award at SBI 2026 Conference
- Commercial Momentum: IceCure anticipates over a 30% increase in U.S. revenue from ProSense® systems and cryoprobes in Q1 2026 compared to the previous year, reflecting a surge in market demand following FDA clearance, which solidifies its position in low-risk breast cancer treatment.
- Cost-Effectiveness Study: A study from Massachusetts General Hospital demonstrated that ProSense® cryoablation can reduce treatment costs by over 50% compared to lumpectomy, winning the Wendell Scott Research Award at SBI 2026, highlighting its significance in cost-effective treatment strategies.
- Clinical Training Workshop: At SBI 2026, IceCure participated in a hands-on workshop titled “How I Do It – Cryoablation,” providing practical guidance on integrating cryoablation into clinical practice, enhancing healthcare professionals' understanding and application of the technology.
- Market Expansion Plans: IceCure plans to close new sales of ProSense® systems in Q2 2026, with an increasing number of installations at leading academic hospitals in the U.S., which is expected to further drive the company's market share in breast cancer treatment.
See More
IceCure Medical Secures $4M in Direct Offering
- Funding Size: IceCure Medical has entered into agreements with healthcare-focused institutional investors to sell 8 million ordinary shares at $0.50 each, with gross proceeds expected to be around $4 million, aimed at strengthening the company's capital base for future growth.
- Warrant Issuance: In this private placement, the company plans to issue Series B and Series C warrants covering up to 8 million shares each, with an exercise price of $0.55 per share, where Series B warrants will expire in five years and Series C in one year, enhancing investor participation incentives.
- Transaction Arrangement: The offering is expected to close on or about March 27, 2026, with Alliance Global Partners acting as the sole placement agent, ensuring a smooth transaction process and boosting market confidence.
- Market Reaction: Despite the financing plan aiding liquidity, IceCure Medical's shares fell by 3.43%, reflecting market concerns over the company's future profitability, which may impact investor confidence.
See More
IceCure Medical Reports Q1 2026 Financial Results
- Revenue Performance: IceCure Medical reported revenue of $911,000 for Q1 2026, indicating stability and potential growth in the market despite fluctuations compared to the previous year.
- Decrease in Sales and Marketing Expenses: Sales and marketing expenses for Q1 2026 were $1,068,000, down from $1,289,000 in Q1 2025, primarily due to reduced consulting fees related to regulatory submissions, showcasing the company's efforts in cost control.
- Increase in Administrative Expenses: General and administrative expenses rose to $1,263,000 in Q1 2026 from $922,000 in Q1 2025, largely driven by increased salary expenses due to fluctuations in the exchange rate between the U.S. dollar and Israeli shekel, reflecting operational cost pressures.
- Overall Operating Expenses Rise: Total operating expenses for Q1 2026 reached $4,542,000, up from $3,875,000 in Q1 2025, primarily due to increases in research and development and administrative expenses, despite a decrease in sales and marketing costs, indicating ongoing investment in R&D to drive future growth.
See More
IceCure Medical Reports Significant Growth in Q1 Performance
- Surge in Customer Accounts: As of Q1 2026, active customer accounts using ProSense® increased by 46% compared to pre-FDA clearance, indicating strong market demand and significant future sales potential.
- Significant Revenue Growth: Revenue for Q1 2026 reached $911,000, a 26% increase from $725,000 in Q1 2025, driven primarily by increased sales in the U.S., Canada, and Mexico, reflecting successful expansion in the North American market.
- Improved Gross Margin: The gross margin increased from 30% in 2025 to 32% in Q1 2026, with gross profit rising 35% to $295,000, indicating substantial progress in cost control and sales efficiency, thereby enhancing the company's financial health.
- Increased R&D Investment: R&D expenses for Q1 2026 were $2,211,000, up from $1,664,000 in 2025, primarily for the CHOICE study, demonstrating the company's ongoing commitment to technological innovation and market expansion.
See More
IceCure Medical to Announce Q1 2026 Results and Host Conference Call
- Earnings Announcement: IceCure Medical plans to release its financial and operational results for the three months ended March 31, 2026, before the Nasdaq opens on May 12, 2026, demonstrating the company's commitment to transparency and information disclosure.
- Conference Call Details: The company will hold a conference call at 11:00 a.m. EDT on the same day to discuss the financial results and other corporate developments, which is expected to attract investor and analyst attention, thereby enhancing market confidence.
- Technological Background: IceCure focuses on developing liquid nitrogen-based cryoablation technology, providing a safe and effective treatment option for tumors, particularly in breast, kidney, bone, and lung cancers, showcasing its market potential.
- Market Outlook: With the increasing demand for minimally invasive procedures, the global sales and marketing of IceCure's ProSense® system will help the company secure a foothold in the competitive medical device market.
See More
IceCure Medical Showcases ProSense® at ASBrS Conference
- FDA-Cleared Innovation: ProSense® is the only FDA-cleared minimally invasive treatment option for low-risk breast cancer, aligning with the trend toward de-escalation in breast cancer treatment, which is expected to enhance market acceptance and drive sales growth.
- Sales Growth Expectations: The company anticipates that U.S. revenue from ProSense® systems and cryoprobes will increase by over 30% in Q1 2026 compared to the same period last year, indicating strong market demand and product recognition.
- Clinical Application Promotion: At the ASBrS 2026 Annual Meeting, IceCure's sponsored cryoablation symposium attracted breast surgeons from leading medical institutions who shared their clinical experiences with ProSense®, further promoting the adoption of this technology.
- Guideline Update: The updated ASBrS Resource Guide includes cryoablation as a recommended treatment option for low-risk early-stage breast cancer, reflecting an increase in clinical evidence and acceptance among surgeons, indicating a promising future for broader application.
See More
IceCure Medical Wins Award at SBI 2026 Conference
- Commercial Momentum: IceCure anticipates over a 30% increase in U.S. revenue from ProSense® systems and cryoprobes in Q1 2026 compared to the previous year, reflecting a surge in market demand following FDA clearance, which solidifies its position in low-risk breast cancer treatment.
- Cost-Effectiveness Study: A study from Massachusetts General Hospital demonstrated that ProSense® cryoablation can reduce treatment costs by over 50% compared to lumpectomy, winning the Wendell Scott Research Award at SBI 2026, highlighting its significance in cost-effective treatment strategies.
- Clinical Training Workshop: At SBI 2026, IceCure participated in a hands-on workshop titled “How I Do It – Cryoablation,” providing practical guidance on integrating cryoablation into clinical practice, enhancing healthcare professionals' understanding and application of the technology.
- Market Expansion Plans: IceCure plans to close new sales of ProSense® systems in Q2 2026, with an increasing number of installations at leading academic hospitals in the U.S., which is expected to further drive the company's market share in breast cancer treatment.
See More
IceCure Medical Secures $4M in Direct Offering
- Funding Size: IceCure Medical has entered into agreements with healthcare-focused institutional investors to sell 8 million ordinary shares at $0.50 each, with gross proceeds expected to be around $4 million, aimed at strengthening the company's capital base for future growth.
- Warrant Issuance: In this private placement, the company plans to issue Series B and Series C warrants covering up to 8 million shares each, with an exercise price of $0.55 per share, where Series B warrants will expire in five years and Series C in one year, enhancing investor participation incentives.
- Transaction Arrangement: The offering is expected to close on or about March 27, 2026, with Alliance Global Partners acting as the sole placement agent, ensuring a smooth transaction process and boosting market confidence.
- Market Reaction: Despite the financing plan aiding liquidity, IceCure Medical's shares fell by 3.43%, reflecting market concerns over the company's future profitability, which may impact investor confidence.
See More
